Summary & Overview
HCPCS J2353: Octreotide Depot Injection, 1 mg
HCPCS Level II code J2353 denotes a 1 mg dose of octreotide in depot form for intramuscular injection. This code captures administration of a long-acting somatostatin analogue used in the management of conditions that benefit from sustained octreotide exposure. Nationally, accurate coding of depot octreotide matters for appropriate drug tracking, claims processing, and care continuity for patients requiring extended-release somatostatin therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for depot octreotide use, typical service settings, and the implications for billing workflow. The publication outlines common billing modifiers and payer considerations when available, summarizes reimbursement benchmarks where provided, and flags policy updates relevant to HCPCS Level II drug coding and coverage.
This summary is intended for billing managers, clinicians involved in drug administration, and policy analysts seeking a focused reference on coding and payer coverage considerations for depot octreotide. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2353 represents an injection of octreotide, depot form for intramuscular injection, 1 mg. The service is a long-acting somatostatin analogue administration intended for conditions that require sustained octreotide release. The service type is medication administration by intramuscular injection. The typical site of service is an outpatient clinical setting such as a clinic, physician office, or outpatient infusion center.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acromegaly or symptomatic carcinoid syndrome requiring long-acting somatostatin analogue therapy. The patient presents to an outpatient endocrinology or oncology clinic for a scheduled intramuscular depot injection of octreotide (long-acting release) to control hormone hypersecretion and related symptoms such as flushing, diarrhea, headache, and excessive growth hormone symptoms. The clinical workflow includes pre-visit verification of indication and recent labs, confirmation of prior authorization and payer coverage, assessment of injection site and contraindications, informed consent discussion, medication reconstitution/preparation by a licensed clinician or pharmacist, administration of J2353 via deep intramuscular injection (typically gluteal), observation for immediate adverse reactions for 15–30 minutes, documentation of lot number, dose, site, and any patient education, and scheduling the next depot dose (commonly every 4 weeks) or adjustment based on clinical response and tolerability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a qualifying E/M visit is performed on the same day as J2353 and is distinct from the injection visit. |